Roshni Kulkarni

5.6k total citations · 1 hit paper
147 papers, 3.4k citations indexed

About

Roshni Kulkarni is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Roshni Kulkarni has authored 147 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Hematology, 35 papers in Genetics and 15 papers in Molecular Biology. Recurrent topics in Roshni Kulkarni's work include Hemophilia Treatment and Research (74 papers), Blood Coagulation and Thrombosis Mechanisms (42 papers) and Platelet Disorders and Treatments (41 papers). Roshni Kulkarni is often cited by papers focused on Hemophilia Treatment and Research (74 papers), Blood Coagulation and Thrombosis Mechanisms (42 papers) and Platelet Disorders and Treatments (41 papers). Roshni Kulkarni collaborates with scholars based in United States, United Kingdom and Canada. Roshni Kulkarni's co-authors include J. Michael Soucie, Jeanne M. Lusher, Bruce L. Evatt, Robert B. Noll, William M. Bukowski, Barbara A. Konkle, Marilyn J. Manco‐Johnson, Johnny Mahlangu, J. Michael Soucie and Scott D. Grosse and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Roshni Kulkarni

141 papers receiving 3.2k citations

Hit Papers

Efanesoctocog Alfa Prophylaxis for Patients with Severe H... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
    2023 100 citations Pratima Chowdary, Roshni Kulkarni et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roshni Kulkarni United States 34 2.3k 788 443 377 220 147 3.4k
Karin Fijnvandraat Netherlands 40 4.1k 1.8× 1.7k 2.2× 590 1.3× 483 1.3× 373 1.7× 220 5.3k
Marjolein Peters Netherlands 36 3.4k 1.5× 995 1.3× 403 0.9× 365 1.0× 452 2.1× 136 4.5k
Rakhi P. Naik United States 22 763 0.3× 924 1.2× 228 0.5× 123 0.3× 139 0.6× 76 1.7k
Jonathan C. Goldsmith United States 24 1.3k 0.6× 1.4k 1.8× 457 1.0× 180 0.5× 135 0.6× 73 2.6k
David Bevan United Kingdom 27 1.4k 0.6× 837 1.1× 200 0.5× 227 0.6× 378 1.7× 78 3.0k
Erik Berntorp Sweden 42 5.5k 2.4× 1.4k 1.7× 190 0.4× 653 1.7× 535 2.4× 183 6.5k
Kate Khair United Kingdom 29 2.0k 0.9× 421 0.5× 143 0.3× 137 0.4× 193 0.9× 152 2.6k
Matthew P. Smeltzer United States 31 1.2k 0.5× 1.5k 1.9× 557 1.3× 253 0.7× 217 1.0× 107 2.8k
Joseph Stanek United States 18 394 0.2× 312 0.4× 243 0.5× 120 0.3× 136 0.6× 151 1.3k
Kath Watson United Kingdom 37 1.4k 0.6× 723 0.9× 189 0.4× 223 0.6× 503 2.3× 79 5.8k

Countries citing papers authored by Roshni Kulkarni

Since Specialization
Citations

This map shows the geographic impact of Roshni Kulkarni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roshni Kulkarni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roshni Kulkarni more than expected).

Fields of papers citing papers by Roshni Kulkarni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roshni Kulkarni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roshni Kulkarni. The network helps show where Roshni Kulkarni may publish in the future.

Co-authorship network of co-authors of Roshni Kulkarni

This figure shows the co-authorship network connecting the top 25 collaborators of Roshni Kulkarni. A scholar is included among the top collaborators of Roshni Kulkarni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roshni Kulkarni. Roshni Kulkarni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manco‐Johnson, Marilyn J., Binh Le, Suchitra Acharya, et al.. (2025). Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort. PubMed. 2(3). 100047–100047.
2.
Kulkarni, Roshni, et al.. (2025). Enhancing Jackfruit Shelf-Life Through Intelligent Packaging: A Review. Food Reviews International. 42(2). 746–772. 1 indexed citations
3.
Carção, Manuel, Roshni Kulkarni, Pablo Rendo, et al.. (2024). A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial. Blood Advances. 8(6). 1494–1503.
4.
Shapiro, Amy D., Roshni Kulkarni, Margaret V. Ragni, et al.. (2023). Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Advances. 7(13). 3049–3057. 4 indexed citations
5.
6.
Susen, Sophie, Roshni Kulkarni, Keiji Nogami, et al.. (2023). OC 69.5 Outcomes in Adult and Adolescent Patients with Severe Hemophilia a in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis from an Observational Study with Factor VIII Prophylaxis. Research and Practice in Thrombosis and Haemostasis. 7. 100442–100442. 1 indexed citations
7.
8.
Roberts, Jonathan, Roshni Kulkarni, Peter A. Kouides, et al.. (2021). Depression and Anxiety in Persons with Von Willebrand Disease. Blood. 138(Supplement 1). 4052–4052. 4 indexed citations
9.
Galen, Karin P. M. van, Roseline d’Oiron, Paula James, et al.. (2021). A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 19(8). 1883–1887. 91 indexed citations
10.
Srivaths, Lakshmi, Charles G. Minard, Sarah H. O’Brien, et al.. (2020). The spectrum and severity of bleeding in adolescents with low von Willebrand factor–associated heavy menstrual bleeding. Blood Advances. 4(13). 3209–3216. 16 indexed citations
11.
Abe, Karon, et al.. (2019). Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease. American Journal of Hematology. 95(1). 10–17. 15 indexed citations
12.
13.
Hermans, Cédric & Roshni Kulkarni. (2018). Women with bleeding disorders. Haemophilia. 24(S6). 29–36. 39 indexed citations
14.
Oldenburg, Johannes, Roshni Kulkarni, Alok Srivastava, et al.. (2017). Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 24(1). 77–84. 38 indexed citations
15.
Kessler, Craig M., et al.. (2017). The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. JMIR Medical Education. 3(1). e6–e6. 2 indexed citations
16.
Srivaths, Lakshmi, Vanessa R. Byams, Jennifer E. Dietrich, et al.. (2017). Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding. Haemophilia. 24(1). 63–69. 15 indexed citations
17.
Pasi, John, Kathelijn Fischer, Margaret V. Ragni, et al.. (2016). Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis. 117(3). 508–518. 29 indexed citations
18.
19.
James, Paula, Raj S. Kasthuri, Rebecca Kruse‐Jarres, et al.. (2013). Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment. Transfusion Medicine and Hemotherapy. 40(5). 352–355. 4 indexed citations
20.
Kulkarni, Roshni, Erik Berntorp, Deborah Brown, et al.. (2001). Therapeutic choices for patients with hemophilia and high‐titer inhibitors. American Journal of Hematology. 67(4). 240–246. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karin Fijnvandraat Breakdown of academic impact, for papers by Marjolein Peters Breakdown of academic impact, for papers by Rakhi P. Naik Breakdown of academic impact, for papers by Jonathan C. Goldsmith Breakdown of academic impact, for papers by David Bevan Breakdown of academic impact, for papers by Erik Berntorp Breakdown of academic impact, for papers by Kate Khair Breakdown of academic impact, for papers by Matthew P. Smeltzer Breakdown of academic impact, for papers by Joseph Stanek Breakdown of academic impact, for papers by Kath Watson
Rankless by CCL
2026